Short Bowel Syndrome

Overview

Short bowel syndrome (SBS) is a state of chronic intestinal failure arising from massive loss of functional small bowel, leaving insufficient absorptive surface to maintain adequate fluid, electrolyte, macronutrient, and micronutrient balance without medical support.

The diagnostic threshold is generally a small bowel remnant of less than 200 cm (normal adult small bowel length is 600–800 cm). However, functional severity depends not only on remnant length but critically on which segment remains, whether the colon is in continuity, and whether the ileocecal valve has been preserved.

SBS may require long-term or permanent parenteral nutrition (PN) — the most complex and costly form of nutritional support, and one that carries significant long-term complications including catheter-related bloodstream infections, PN-associated liver disease, and metabolic bone disease.

↑ Back to Table of Contents

Causes and Anatomy of Loss

Three major mechanisms account for the vast majority of adult SBS:

Crohn's Disease (most common adult cause)

• Repeated surgical resections over years → cumulative bowel loss
• Terminal ileum (most commonly affected segment in Crohn's) has critical functions: B12 absorption, bile acid reabsorption, ileal brake hormone (glucagon-like peptide-1 (GLP-1), PYY) secretion
• Crohn's-related SBS is typically gradual and somewhat predictable

Mesenteric Ischemia / Volvulus / Trauma

• Acute total or near-total small bowel loss in a single catastrophic event
• Superior mesenteric artery (SMA) occlusion → massive ischemia
• Midgut volvulus (more common in neonates/children)
• Abdominal trauma with vascular injury

Radiation Enteritis

• Late complication of pelvic/abdominal radiation (cervical, prostate, rectal cancers)
• Progressive fibrosis + endarteritis → malabsorption + strictures
• Bowel resection of irradiated segments → SBS

Less common causes: necrotizing enterocolitis (neonates/premature infants), adhesion-related volvulus, tumors, bypass surgery complications.

↑ Back to Table of Contents

Anatomical Types and Severity

The remaining anatomy after intestinal loss defines three functional SBS types:

Type 1 — End-Jejunostomy (most severe)

• No colon in continuity; entire ileum + colon removed
• Massive, high-output fluid + electrolyte losses (3–6 L/day stomal output)
• Dependent on long-term PN; most difficult to wean
• Bile acid reabsorption completely abolished → fat malabsorption + deficiency of fat-soluble vitamins (A, D, E, K)
• Remnant jejunum >100 cm offers more adaptation potential than <100 cm

Type 2 — Jejuno-Colonic Anastomosis (moderate)

• Ileum removed but colon intact (absorbs some fluid/electrolytes + short-chain fatty acids from bacterial fermentation)
• Colon provides significant energy salvage via fermentation of malabsorbed carbohydrates
• Diarrhea less severe than Type 1, but D-lactic acidosis risk (bacterial overgrowth + excess carbohydrate fermentation)
• Bile acid malabsorption → cholerheic diarrhea + oxalate hyperabsorption → calcium oxalate kidney stones

Type 3 — Jejuno-Ileal Anastomosis (mildest)

• Both ileum preserved (or portion) + colon retained
• Ileocecal valve preservation reduces bacterial overgrowth + slows transit
• Best functional prognosis; some patients wean PN fully

↑ Back to Table of Contents

Pathophysiology: Losses and Hypergastrinemia

Fluid and Electrolyte Losses

• Normal: jejunum absorbs 5–6 L/day; terminal ileum absorbs bile acids + Na/Cl; colon salvages 1–2 L/day
• SBS: net secretion can exceed intake — jejunum becomes net secretor below certain luminal sodium concentrations (oral rehydration solution must be >90 mEq/L Na to drive absorption rather than secretion)
• Stomal output monitoring and sodium replacement are central to management

Hypergastrinemia

• Loss of ileum removes enteric feedback inhibition on gastric acid secretion
• Massive acid hypersecretion in acute SBS → peptic ulceration + deactivation of pancreatic enzymes
• Proton pump inhibitors (PPIs) are a standard part of early SBS management (may be weaned as adaptation proceeds)

Small Intestinal Bacterial Overgrowth (SIBO)

• Common in SBS, especially without ileocecal valve
• Contributes to D-lactic acidosis, bloating, diarrhea, nutritional deficiency
• Treated with antibiotic cycling (rifaximin, metronidazole, ciprofloxacin)

Oxalate Nephropathy (Type 2 SBS with colon in continuity)

• Malabsorbed fat binds luminal calcium → free oxalate absorbed by colon → calcium oxalate urolithiasis
• Managed with a low-oxalate diet + calcium supplementation with meals

↑ Back to Table of Contents

Intestinal Adaptation

Intestinal adaptation is the process by which the remnant bowel increases absorptive capacity over time — the biological rationale for aggressive enteral feeding from the earliest safe opportunity:

Timing: begins within days of resection; most adaptation occurs in the first 1–2 years.

Structural Changes

• Villous hyperplasia (increased villous height, crypt depth, mucosal surface area)
• Bowel wall dilation + elongation
• Upregulation of nutrient transporters (SGLT-1, GLUT-5, DPPIV)

Drivers of Adaptation

• Enteral nutrients (essential — luminal stimulation drives adaptation; PN alone does not)
• GLP-2 (glucagon-like peptide 2, secreted by L-cells in ileum/colon) — intestinotrophic hormone; basis for teduglutide therapy
• Epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1)
• Bile acids (luminal trophic effect)

Clinical implication: enteral feeding (oral or tube) is started as early as the surgical team permits — even minimal enteral intake drives adaptation faster than PN alone.

↑ Back to Table of Contents

Nutritional Management and Parenteral Nutrition

Phase 1 — Acute (0–3 months, high fluid/electrolyte losses)

• Parenteral nutrition provides life-sustaining calories, protein, vitamins, minerals
• Meticulous fluid/electrolyte balance (Na, K, Mg, Ca, Zn replace losses)
• Oral intake gradually introduced: small, frequent, isotonic, salty meals
• Oral rehydration solutions with >90 mEq/L sodium (not standard sports drinks, which are too low in Na)

Phase 2 — Adaptation (3–12+ months)

• Gradual increase in enteral/oral intake
• PN weaned as enteral intake improves — intestinal function monitored by urine output + electrolytes
• In patients whose colon remains in continuity, short bowel guidelines describe a diet high in complex carbohydrate and lower in fat: the colon ferments the unabsorbed carbohydrate and recovers energy from it, while unabsorbed fat in the colon worsens diarrhoea and raises oxalate absorption
• Type 1 (end-jejunostomy): high-fat diet better tolerated (fat slows gastric emptying and reduces stomal output)

Micronutrient Monitoring (all SBS patients)

• B12 (ileum critical for absorption — given as a monthly intramuscular (IM) injection when the ileum has been removed)
• Fat-soluble vitamins (A, D, E, K) — supplementation and monitoring
• Zinc, magnesium, selenium (high stomal losses)
• Iron (supplementation + monitoring)
• Essential fatty acids

PN-Associated Complications

• Central line infections (CLABSI) — preventable with sterile technique + ethanol lock protocols
• PN-associated liver disease (PNALD/IFALD) — driven by manganese toxicity, phytosterols in lipid emulsions; a mixed-oil lipid emulsion (soybean, medium-chain triglyceride, olive and fish oils) reduces PNALD
• Metabolic bone disease (osteoporosis) from Ca/vitamin D losses
• Cholelithiasis (lack of enteral stimulation reduces bile flow)

↑ Back to Table of Contents

Medications

Antidiarrheals (reduce intestinal transit + stomal output)

• Loperamide (first-line; 4 mg up to 4×/day — taken 30–60 min before meals for maximal effect)
• Diphenoxylate/atropine (alternative)
• Codeine (more potent; addiction risk)
• Cholestyramine (only in jejuno-colonic SBS — binds malabsorbed bile acids; not used in end-jejunostomy — depletes bile acid pool)

Antisecretory

• Proton pump inhibitors: pantoprazole intravenous (IV) initially → oral — used for hypergastrinemia (reduce acid-peptic complications + volume losses)
• Octreotide (somatostatin analogue): reduces ileostomy/stomal output by 50–80%; long-term use carries a cholelithiasis risk; used when other measures are insufficient

↑ Back to Table of Contents

Teduglutide (GLP-2 Analogue)

Teduglutide is a recombinant GLP-2 analogue approved in 2012 (U.S. Food and Drug Administration, FDA) for adult SBS patients dependent on parenteral support.

Mechanism

• GLP-2 receptor agonism → intestinotrophic effect (increases villous height, crypt depth, mucosal blood flow)
• Reduces gastric emptying + gastric acid secretion
• Increases intestinal absorptive capacity

Clinical Evidence

• STEPS trial (NCT00798967): 63% of teduglutide patients achieved ≥20% reduction in PN volume vs. 30% placebo; mean reduction 4.4 L/week.
• STEPS-2 (24-month extension): sustained benefit; 13 of 88 enrolled patients achieved full enteral autonomy (no longer needed parenteral support).
• STEPS-3: a 1-year open-label extension in 14 adults; 2 patients achieved independence from parenteral support.
• Children: the 2019 U.S. Food and Drug Administration approval for children 1 year of age and older followed a separate 24-week phase III pediatric study (Kocoshis et al., 2020); the current label covers adults and children 1 year and older.

Dosing: 0.05 mg/kg/day subcutaneous injection; the label gives 0.025 mg/kg/day when the estimated glomerular filtration rate (eGFR) is below 60 mL/min/1.73 m².

Monitoring: GLP-2 is intestinotrophic, and the U.S. label warns of acceleration of neoplastic growth. For adults it lists a colonoscopy and upper GI endoscopy with removal of polyps within 6 months before starting, again after 1 year of treatment, and then no less often than every 5 years. For children it lists fecal occult blood testing before starting and every year, with colonoscopy/sigmoidoscopy after 1 year and every 5 years after that. Bilirubin, alkaline phosphatase, lipase and amylase are checked before starting and every 6 months.

Contraindications and warnings: the U.S. label lists no contraindications. Its warnings include acceleration of neoplastic growth (the label states that teduglutide is stopped if an intestinal cancer is found), intestinal obstruction, gallbladder, bile-duct and pancreatic disease, fluid overload including heart failure, and increased absorption of oral medicines.

↑ Back to Table of Contents

Surgical Options

Serial Transverse Enteroplasty (STEP Procedure)

• Lengthens and tapers a dilated bowel segment using linear staplers in alternating transverse applications
• Increases functional surface area + slows transit
• Best for patients with dilated remnant bowel ≥40 cm
• Can allow PN weaning in 30–50% of carefully selected patients
• Can be repeated if bowel re-dilates

Intestinal Lengthening and Tapering (Bianchi Procedure)

Alternative bowel-lengthening operation; now largely replaced by STEP in most centers.

Intestinal Transplantation

• Last resort for patients with irreversible intestinal failure + life-threatening PN complications
• Indications: recurrent line sepsis, IFALD (intestinal failure-associated liver disease), loss of venous access
• Combined liver-intestine transplant if IFALD is irreversible
• 5-year graft survival ~50%; immunosuppression complications significant
• Multidisciplinary intestinal rehabilitation programs delay/avoid transplantation in many patients

↑ Back to Table of Contents

Key Research Papers

1. Jeppesen PB et al. "Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure." Gastroenterology. 2012;143(6):1473–1481.e3. — PubMed PMID: 22982184
2. O'Keefe SJ et al. "Short bowel syndrome and intestinal failure: consensus definitions and overview." Clin Gastroenterol Hepatol. 2006;4(1):6–10. — PubMed PMID: 16431298
3. Pironi L et al. "ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults." Clin Nutr. 2015;34(2):171–180. — PubMed PMID: 25311444
4. Tappenden KA. "Intestinal adaptation following resection." JPEN J Parenter Enteral Nutr. 2014;38(1 Suppl):23S–31S. — PubMed PMID: 24586019
5. Kim HB, Fauza D, Garza J, et al. "Serial transverse enteroplasty (STEP): a novel bowel lengthening procedure." J Pediatr Surg. 2003;38(3):425–429. — PubMed PMID: 12632361
6. Buchman AL et al. "AGA technical review on short bowel syndrome and intestinal transplantation." Gastroenterology. 2003;124(4):1111–1134. — PubMed PMID: 12671904
7. Messing B et al. "Long-term survival and parenteral nutrition dependence in adult patients with the short bowel syndrome." Gastroenterology. 1999;117(5):1043–1050. — PubMed PMID: 10535866
8. Joly F et al. "Tube feeding improves intestinal absorption in short bowel syndrome patients." Gastroenterology. 2009;136(3):824–831. — PubMed PMID: 19046971
9. Nightingale J, Woodward JM. "Guidelines for management of patients with a short bowel." Gut. 2006;55(Suppl 4):iv1–12. — PubMed PMID: 16837533
10. Scolapio JS. "Current update of short-bowel syndrome." Curr Opin Gastroenterol. 2004;20(2):143–145. — PubMed PMID: 15703636
11. Koffeman GI et al. "Classification, epidemiology and aetiology." Best Pract Res Clin Gastroenterol. 2003;17(6):879–893. — PubMed PMID: 14642855
12. Schwartz LK, O'Keefe SJ, Fujioka K, et al. "Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome." Clin Transl Gastroenterol. 2016;7(2):e142. — PubMed PMID: 26844839
13. Seidner DL, Fujioka K, Boullata JI, et al. "Reduction of Parenteral Nutrition and Hydration Support and Safety With Long-Term Teduglutide Treatment in Patients With Short Bowel Syndrome-Associated Intestinal Failure: STEPS-3 Study." Nutr Clin Pract. 2018;33(4):520–527. — PubMed PMID: 29761915
14. Kocoshis SA, Merritt RJ, Hill S, et al. "Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24-Week, Phase III Study." JPEN J Parenter Enteral Nutr. 2020;44(4):621–631. — PubMed PMID: 31495952
15. Teduglutide for injection, U.S. prescribing information (revised September 2025). DailyMed, U.S. National Library of Medicine. — DailyMed label

↑ Back to Table of Contents

Connections

• Gastroenterology
• Crohn's Disease
• Small Intestinal Bacterial Overgrowth
• Celiac Disease
• Ulcerative Colitis
• Glutamine
• Vitamin B12
• Zinc

↑ Back to Table of Contents

Featured Videos

Featured videos will be added shortly.